image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.734
4.11 %
$ 4.07 M
Market Cap
-0.27
P/E
1. INTRINSIC VALUE

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.[ Read More ]

The intrinsic value of one BFRI stock under the base case scenario is HIDDEN Compared to the current market price of 0.734 USD, Biofrontera Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BFRI

image
FINANCIALS
34.1 M REVENUE
18.82%
-22.7 M OPERATING INCOME
-1.32%
-20.1 M NET INCOME
-3045.47%
-24.9 M OPERATING CASH FLOW
-53.68%
619 K INVESTING CASH FLOW
112.01%
8.41 M FINANCING CASH FLOW
-40.01%
9.01 M REVENUE
14.96%
-4.96 M OPERATING INCOME
2.19%
-5.67 M NET INCOME
-2105.84%
-1.21 M OPERATING CASH FLOW
74.41%
0 INVESTING CASH FLOW
100.00%
-298 K FINANCING CASH FLOW
-5.64%
Balance Sheet Decomposition Biofrontera Inc.
image
Current Assets 23.1 M
Cash & Short-Term Investments 1.42 M
Receivables 5.16 M
Other Current Assets 16.5 M
Non-Current Assets 4.86 M
Long-Term Investments 0
PP&E 1.75 M
Other Non-Current Assets 3.11 M
Current Liabilities 18.1 M
Accounts Payable 9.01 M
Short-Term Debt 5.29 M
Other Current Liabilities 3.8 M
Non-Current Liabilities 5.05 M
Long-Term Debt 804 K
Other Non-Current Liabilities 4.25 M
EFFICIENCY
Earnings Waterfall Biofrontera Inc.
image
Revenue 34.1 M
Cost Of Revenue 17.4 M
Gross Profit 16.6 M
Operating Expenses 40 M
Operating Income -22.7 M
Other Expenses -2.55 M
Net Income -20.1 M
RATIOS
48.80% GROSS MARGIN
48.80%
-66.56% OPERATING MARGIN
-66.56%
-59.09% NET MARGIN
-59.09%
-420.01% ROE
-420.01%
-72.07% ROA
-72.07%
-241.72% ROIC
-241.72%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Biofrontera Inc.
image
Net Income -20.1 M
Depreciation & Amortization 1.06 M
Capital Expenditures -5 K
Stock-Based Compensation 1.04 M
Change in Working Capital -4.39 M
Others -14.5 M
Free Cash Flow -24.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Biofrontera Inc.
image
BFRI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Biofrontera Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript Biofrontera Inc. (NASDAQ:BFRI ) Q3 2024 Earnings Conference Call November 14, 2024 10:00 AM ET Company Participants Andrew Barwicki - Investor Relations Hermann Luebbert - Chief Executive Officer, Chairman and Founder Fred Leffler - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Bruce Jackson - The Benchmark Company Operator Welcome to the Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this event is being recorded. seekingalpha.com - 2 days ago
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $4.64 per share a year ago. zacks.com - 3 days ago
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update WOBURN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update. globenewswire.com - 3 days ago
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time. accesswire.com - 2 weeks ago
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of PDT, today announced top-line results in its Phase 3 study of the use of Ameluz® with the BF-RhodoLED® lamp in the treatment of sBCC (study ALA-BCC-CT013). globenewswire.com - 2 weeks ago
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announced today that the database for the treatment phase of study ALA-BCC-CT013 has been locked. globenewswire.com - 1 month ago
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's sNDA to increase the maximally approved dosage from one to three tubes of Ameluz® per treatment. globenewswire.com - 1 month ago
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that management will present at the 3rd Annual ROTH Healthcare Opportunities Conference to be held at the Metropolitan Club in New York, NY. Date: October 9, 2024 Time of Presentation: 12:30 - 1:10 PM ET Format: Live Presentation 1x1 Meetings: Please contact your Roth representative About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. accesswire.com - 1 month ago
Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript Biofrontera Inc. (NASDAQ:BFRI ) Q2 2024 Earnings Conference Call August 15, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - CEO, Chairman and Founder Fred Leffler - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Biofrontera Inc. Second Quarter 2024 Financial Results and Business Update Conference Call. All participants will be in a listen-only mode. seekingalpha.com - 3 months ago
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and six months ended June 30, 2024 and provided a business update. globenewswire.com - 3 months ago
Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024 WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024. The results will be released after the market close on Wednesday, Aug 14 and the company will host a conference call on Thursday, August 15 at 10:00am Eastern Time. accesswire.com - 3 months ago
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the launch of its FDA-approved RhodoLED XL, a red light emitting LED lamp. globenewswire.com - 4 months ago
8. Profile Summary

Biofrontera Inc. BFRI

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 4.07 M
Dividend Yield 0.00%
Description Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Contact 120 Presidential Way, Woburn, MA, 01801 https://www.biofrontera.us.com
IPO Date Oct. 29, 2021
Employees 83
Officers Ms. Erica F. Gates CPA, M.B.A. Senior Director of Finance & Principal Accounting Officer Mr. Eugene Frederick Leffler III Chief Financial Officer Mr. Daniel Hakansson J.D. General Counsel & Head of Compliance Mr. Mark Baldyga Vice President of Sales & Marketing Dr. Hermann Luebbert Ph.D. Chief Executive Officer, President & Executive Chairman Ms. Alycia Torres Vice President of Administration Mr. Jon Lyons M.B.A., Ph.D. Vice President of Scientific & Medical Affairs